Contribution to a book

DZNE-2021-00019

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Therapies for prion diseases.

Zafar, S. (First author)DZNE* ; Noor, A.DZNE* ; Zerr, I. (Last author)DZNE*

2019
Elsevier Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/B978-0-444-64012-3.00004-6

Abstract: Recent advances in understanding of the molecular biology of prion diseases and improved clinical diagnostic techniques might allow researchers to think about therapeutic trials in Creutzfeldt-Jakob disease (CJD) patients. Some attempts have been made in the past and various compounds have been tested in single case reports and patient series. Controlled trials are rare. However, in the past few years, it has been demonstrated that clinical trials are feasible. The clinicians might face several specific problems when evaluating the efficacy of the drug in CJD, such as rareness of the disease, lack of appropriate preclinical tests and heterogeneous clinical presentation in humans. These problems have to be carefully addressed in future.

Keyword(s): Animals (MeSH) ; Anti-Bacterial Agents: therapeutic use (MeSH) ; Brain: pathology (MeSH) ; Clinical Trials as Topic: methods (MeSH) ; Creutzfeldt-Jakob Syndrome: diagnosis (MeSH) ; Creutzfeldt-Jakob Syndrome: drug therapy (MeSH) ; Humans (MeSH) ; PrPSc Proteins (MeSH) ; Prion Diseases: diagnosis (MeSH) ; Prion Diseases: drug therapy (MeSH) ; Quinine: analogs & derivatives (MeSH) ; Quinine: therapeutic use (MeSH) ; Sulfonylurea Compounds: therapeutic use (MeSH) ; Disease heterogeneity ; PrP(Sc) ; Prion ; Survival ; Therapy ; Anti-Bacterial Agents ; PrPSc Proteins ; Sulfonylurea Compounds ; Quinine

---

Contributing Institute(s):

1. Translational Studies and Biomarkers (AG Zerr)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2019

---

Database coverage:
; NCBI Molecular Biology Database ; SCOPUS

---